NEWS HIGHLIGHTS
Published Studies Related to Rimso-50 (Dimethyl Sulfoxide)
Dimethyl sulfoxide with lignocaine versus eutectic mixture of local anesthetics: prospective randomized study to compare the efficacy of cutaneous anesthesia in shock wave lithotripsy. [2011.06]
The objective of the study was to compare the efficacy of dimethyl sulfoxide (DMSO) mixed with lignocaine and eutectic mixture of local anesthetics (EMLA) cream as topically applied surface anesthetics in relieving pain during shock wave lithotripsy (SWL) in a prospective randomized study...
Effects of therapeutic pulsed ultrasound and dimethylsulfoxide (DMSO) phonophoresis on parameters of oxidative stress in traumatized muscle. [2010.01]
Many studies have demonstrated an increase in reactive oxygen species (ROS) and oxidative damage markers after muscle damage. Phonophoresis aims to achieve therapeutically relevant concentrations of the transdermally introduced drug in the tissues subjected to the procedure by the use ultrasound waves...
Evaluation of efficacy and safety of zinc gluconate associated with dimethyl sulphoxide for sexually mature canine males chemical neutering. [2009.12]
The aim of this research was to evaluate the efficacy of zinc gluconate associated with dimethyl sulphoxide (DMSO) for chemical neutering in canine males. Fifteen sexually mature male dogs were divided in two groups, named control and treated... Ultrasound and histopathology analyses of testicles for the treated group revealed more intense injuries when compared with the control group, with compromised testicular parenchyma and a decrease of germ cell number leading to total atrophy, indicating that the treatment reduced the fertilizing potential of male dogs, promoting a possible subfertile status.
Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. [2009.08]
We completed a phase 1/2 trial to evaluate the safety and potential efficacy of direct intravesical instillation of a botulinum type A toxin/dimethyl sulfoxide (DMSO) solution for treatment of idiopathic detrusor overactivity in women. Twenty-five women with medication-resistant, urodynamic-confirmed idiopathic detrusor overactivity were enrolled...
Synthesis and detection of toltrazuril sulfone and its pharmacokinetics in horses following administration in dimethylsulfoxide. [2009.08]
Triazine-based antiprotozoal agents are known for their lipophylic characteristics and may therefore be expected to be well absorbed following oral administration. However, although an increase in lipid solubility generally increases the absorption of chemicals, extremely lipid-soluble chemicals may dissolve poorly in gastrointestinal (GI) fluids, and their corresponding absorption and bioavailability would be low...
Clinical Trials Related to Rimso-50 (Dimethyl Sulfoxide)
Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis [Recruiting]
The purpose of this study is to compare the efficacy of hyperbaric oxygen therapy (HBOT) to
intravesical Dimethyl Sulfoxide (DMSO) instillation for the treatment of patients who
suffers from Interstitial Cystitis / Painful bladder syndrome.
DMSO Efficacy in IC/PBS Patients During and After Treatment [Recruiting]
The purpose of this study is to examine the efficacy of dimethylsulphoxide (DMSO) cocktail
in patients with interstitial cystitis during the treatment period (12 weeks) and after it
(at 6 weeks, 3, 6 and 12 month).
Over Active Bladder Instillation Study - Botox [Recruiting]
The purpose of this study is to determine whether women with overactive bladder (OAB) who
receive direct instillation via a catheter of a Botulinum-A Toxin (Botox) with Dimethyl
Sulfoxide (DMSO) solution experience significantly better improvement of their OAB symptoms
when compared to a similar group of women with OAB who receive instillation of DMSO only.
A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People [Recruiting]
This phase I study is the first step to determine if Opal immunotherapy may have potential
utility as a treatment for HIV. Although effective treatments for HIV infection exist, they
are limited by the requirement for life-long daily treatment, cost, side effects, and the
development of resistance.
There is a need for therapeutic approaches that induce or enhance T-cell immunity to control
HIV disease. Overlapping Peptide-pulsed Autologous Cells (Opal) is a technique where
autologous peripheral blood mononuclear cells (PBMC) or whole blood is pulsed with sets of
overlapping peptides spanning whole proteins of HIV.
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies [Not yet recruiting]
This is an open-label, randomized, single-dose, 2-treatment, 2-period, 2-way crossover study
with incomplete wash-out in subjects with solid tumors to determine the relative
bioavailability of test formulation with lower dimethyl sulfoxide (DMSO) content as compared
with standard reference formulation trametinib.
Approximately 18 subjects will be randomized to receive either a single dose of Treatment A
(standard target DMSO content [theoretical 11. 3%] formulation of GSK1120212B) or a single
dose of Treatment B (lower DMSO Content [approximately 9. 5%] formulation of GSK1120212B)
followed by a 7 day incomplete wash-out period, then a single dose of the other treatment.
Administration of the dose under fasted conditions in Periods 1 and 2 will be only on Day 1
followed by 7 days of serial blood sampling for PK analysis of plasma trametinib. Safety
assessments, including assessment of AEs, clinical laboratory (hematology and clinical
chemistry) and vital signs, will be made throughout the study.
After a subject completes the study, he or she may be eligible to enter study MEK114375, an
open-label rollover study of trametinib (no wash-out period or follow-up visit required) and
continue receiving trametinib. For those subjects who wish to discontinue or complete the
current study and choose not enter the rollover study, a follow-up visit should be performed
within 21 days after receiving the last dose of study treatment.
|
